Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 399,432
  • Shares Outstanding, K 112,834
  • Annual Sales, $ 20 K
  • Annual Income, $ -95,060 K
  • EBIT $ -90 M
  • EBITDA $ -94 M
  • 60-Month Beta 0.13
  • Price/Sales 9,645.93
  • Price/Cash Flow N/A
  • Price/Book 1.81

Options Overview Details

View History
  • Implied Volatility 117.99% (-256.26%)
  • Historical Volatility 95.85%
  • IV Percentile 53%
  • IV Rank 17.81%
  • IV High 444.78% on 12/29/25
  • IV Low 47.16% on 08/20/25
  • Expected Move (DTE 4) 0.29 (7.45%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 10,297
  • Volume Avg (30-Day) 4,858
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 141,689
  • Open Int (30-Day) 143,297
  • Expected Range 3.59 to 4.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.26
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year -0.26
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.41 +13.62%
on 03/06/26
4.83 -19.67%
on 02/24/26
-0.81 (-17.27%)
since 02/09/26
3-Month
3.41 +13.62%
on 03/06/26
6.44 -39.75%
on 01/23/26
-1.64 (-29.71%)
since 12/09/25
52-Week
2.90 +33.79%
on 06/26/25
7.73 -49.81%
on 06/25/25
-1.69 (-30.34%)
since 03/07/25

Most Recent Stories

More News
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder...

ALT : 3.88 (+9.60%)
Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.88 (+9.60%)
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.88 (+9.60%)
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.88 (+9.60%)
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.88 (+9.60%)
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced...

ALT : 3.88 (+9.60%)
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Improvements observed in key  non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks...

ALT : 3.88 (+9.60%)
Altimmune Announces CEO Transition and Succession Plan

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01,...

ALT : 3.88 (+9.60%)
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...

ALT : 3.88 (+9.60%)
Metabolic Reset: Cell Therapies and Novel Drugs Reshape Chronic Disease Market

VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...

AVAI : 0.3654 (+0.83%)
TNDM : 20.88 (-1.23%)
CRNX : 38.22 (-0.03%)
MDGL : 433.20 (+0.09%)
ALT : 3.88 (+9.60%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 4.26
2nd Resistance Point 4.07
1st Resistance Point 3.98
Last Price 3.88
1st Support Level 3.70
2nd Support Level 3.51
3rd Support Level 3.42

See More

52-Week High 7.73
Fibonacci 61.8% 5.88
Fibonacci 50% 5.32
Fibonacci 38.2% 4.75
Last Price 3.88
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar